# A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

> **NCT01876550** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 1902 (actual)

## Conditions studied

- Secondarily Infected Traumatic Skin Lesions

## Interventions

- **DRUG:** Mupirocin Calcium Cream, 2%
- **DRUG:** Bactroban® Cream
- **DRUG:** Cream vehicle of test product

## Key facts

- **NCT ID:** NCT01876550
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-02
- **Final completion:** 2019-05-06
- **Target enrollment:** 1902 (ACTUAL)
- **Last updated:** 2019-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01876550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01876550, "A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01876550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*